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Both the arms received concurrent chemo-radiation. 
Chemotherapy with inj Cisplatin 35 mg/m² weekly IV infusion 
was given as a radiosensitizer before Radiotherapy for 6 
cycles and external beam radiotherapy 69.99-70Gy in 33-35 
fractions 2 - 2.121Gy/fraction using Linear accelerator of 6MV 
photons by Conventional arm received standard regimen 5 
fractions/week with overall treatment time of 6 weeks and 
Accelerated arm received 6fractions/week with overall 
treatment time of 7weeks.  
Patients were evaluated in both the arms for early tumor 
response and acute Toxicities 
 
Results: The mean age of patients were 53.44 
years,76.60%were male and 23.4% were female . 
Concurrent chemoradiation using accelerated fractionation 
showed higher percentage of complete response rate , in 
stage III-100%, IVA-88.50%and IVB- 50%,were as in 
conventional fractionation it was in stage III-87.50% and IVA-
80.00%. 
According to site complete response rate in oral cavity 
87.50%and 50.00% , oropharynx 92.90% and 72.70% in 
accelerated fractionation and conventional fractionations 
respectively. 
Total number of cycles of chemotherapy received were same 
in both the arms. There was significant weight loss during 
treatment in accelerated fractionation compared to 
conventional fractionation arm. 
 
Conclusion: In our study, Locally advanced head and neck 
cancers showed better early tumor response with acceptable 
acute toxicities when treated with concurrent 
chemoradiation using accelerated fractrationation compared 
to conventional fraction and the quality of life was not 
stastically different in both the arms. 
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Purpose or Objective: It is established that in the 
management of locally advanced head and neck cancer (HNC) 
patients, 18F-FDG-PET/CT (FDG) plays a significant role in 
the pre-treatment setting to predict outcome and prognosis 
and at the end of the chemo-radiotherapy (CRT) to assess the 
tumor response. This systematic review aims to evaluate the 
use of FDG acquired during CRT, ad interim FDG (FDGint), 
with the aim to identify tumor responsiveness in an early 
stage of the treatment in order to allow modification of the 
treatment plan and/or to setup alternative therapeutic 
strategies to enhance the therapeutic ratio.  
 
Material and Methods: Data search was performed in PubMed 
for full original papers published from 2005 up to August 
2015, written in English and based on the use of 3D hybrid 
PET/CT only, with eight different combination of keywords. 
The literature search brought 568 articles. Twenty-one 
original papers fulfilled the inclusion criteria: 8 studies 
investigated the predictive role of FDGint assessing 
correlations between metabolic variations and clinical 
outcomes, 7 studies draw conclusions about a potential role 
of response assessment during RT for treatment adaptation 
without reporting any correlation with the clinical data, and 
6 studies were focused on the use of FDGint for biology-
guided adaptive RT. 
 
Results: The results of the analysis considering only the 
papers focusing on the predictive role of FDGint are reported 
in the table. All patients underwent at least a FDG at 
baseline, and one at a dose in the range of 10-20 Gy (early 
PETint), or in the range of 40-50 Gy (late PETint). Most of the 
studies reported a qualitative or semi-quantitative method of 
delineation of the FDG uptake, using a threshold value of the 
SUVmax, usually 40% or 50%. All the studies have in common 
the SUVmax and its variation as the main parameters 
considered for FDG evaluation, although the largest and first 
study evaluating all metabolic parameters of FDGint, found 
that tumor lesion glycolysis was a better and statistically 
more significant predictor of outcome than SUVmax. Two 
papers comparing FDGint with FLTint revealed that reduced 
FLT SUV preceded reduced FDG uptake, suggesting that 
FLTint is expected to assess the therapeutic response much 




Conclusion: Most of the works confirmed the value of FDGint 
in predicting the response to CRT, while few highlighted the 
poor prognostic value of FDGint compared to FDG acquired 2-
3 months after the end of CRT which revealed a strong 
correlation with local and regional control and with survival. 
Although the best timing to assess tumor response during RT 
remains a matter of debate, the two week time point seems 
most favorable, also because there is still sufficient 
opportunity for adaptation of the treatment strategy. Such 
contradictory findings deserve to be further analyzed and 
confirmed in a more numerous and homogeneous series 
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Purpose or Objective: The radiation therapy of head and 
neck tumors is burdened by high toxicity to organs at risk 
(OARs) with consequent administered dose limitations to the 
target and compromised clinical outcome. We investigated 
the contribution of functional/biological imaging obtained by 
Positron Emission Tomography (PET/CT) in Gross Tumor 
Volume (GTV) and Clinical Target Volume (CTV) definition of 
primary tumor and regional lymph nodes in head and neck 
cancer, for a more accurate target delimitation resulting in 
lower toxicity to OARs. 
 
Material and Methods: From March 2103 to June 2014 we 
examined 51 patients with head and neck cancer and defined 
clinical volumes with the aid of only morphological CT images 
and with the aid of diagnostic PET/CT images. Then we 
evaluated, through tests of statistical significance, the 
overlap of GTV and CTV obtained with each of the two 
methods respectively. Moreover usefulness of PET/CT in 
preventing geographic errors for a more accurate target 
definition, resulting in peritumoral tissues preservation and 
less toxicity to the OARs, was evaluated as well. The 
influence of two different imaging techniques in TNM staging, 
which is important for treatment planning, was investigated. 
 
Results: In 33 of 51 patients the TNM staging obtained by 
PET/CT was similar to that performed by CT images, but in 
39% of the cases the primary tumor GTV defined by PET/CT 
was significantly smaller and restricted compared to that 
defined by CT only (p <0.016). Due to the better GTV 
definition in terms of size and location, the OARs are 
potentially better preserved. In 12 patients the more 
accurate definition of tumor margins made possible by 
PET/CT produced a different T than that obtained with CT 
evaluation only; in 6 patients PET/CT identified metastases 
to regional lymph nodes not assessed with CT images only. It 
was not observed significant variation of the nodal volumes. 
 
Conclusion: The use of PET/CT imaging allows the realization 
of more precise target volume and better defined clinical 
volumes, with a possible better preservation of the OARs and 
lower toxicity. Functional imaging PET/CT helps the radiation 
oncologist not only in the process of treatment planning, but 
has the advantage of identify treatable disease not 
highlighted on morphological CT images. It is therefore 
recommended to use a PET/CT scan in the radiotherapy 
planning process in order to achieve a more appropriate 
treatment planning in head and neck tumors. 
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Purpose or Objective: Concomitant radiotherapy + 
cetuximab association has shown superiority to exclusive 
radiotherapy for locally advanced head and neck cancers 
(LAHNC). Data on this association are scarce for the elderly 
despite its rising incidence. Initial clinical trials that led to its 
approval have not included patients>70 years. The objective 
of this study was to assess efficacy and toxicity of 
concomitant radiotherapy and cetuximab for patients 
aged>70 years with LAHNC 
 
Material and Methods: A retrospective monocentric data 
collection was performed in the Antoine Lacassagne center, 
France. Inclusion criterias were: age>70 years at time of 
diagnosis, histologically proven LAHNC, treated with 
radiotherapy combined with cetuximab. Non-inclusion 
criterias were: previous radiotherapy and metastases at time 
of diagnosis 
 
Results: Thirty-five patients were included between 2008 and 
2012. Median follow up was 22 months. Median age was 74 
years (70-86). Median performance status was 1(0-2). 
Female/male sex ratio was 0.34. Tumor sites were: 
Oropharynx(57.1%), larynx(20%), hypopharynx(14.3%), oral 
cavity(2.9%), rhinopharynx(2.9%), lymph node with unknown 
primary(2.9%). Using TNM classification, tumors were: 
T1(5.9%), T2(35.3%), T3(35.3%), T4(22.9%), N0(28.6%), 
N1(8.6%), N2(48.6%), N3(14.3%). Median radiotherapy dose 
was 70 Gy(60-70). 40% of patients were treated with 
intensity-modulated radiotherapy, the rest were treated with 
conventional 3D radiotherapy. 94.3% of patients paused 
radiotherapy due to toxicity. 29% had a cetuximab dose-
reduction and 1 patient had a definitive interruption. Median 
survivals were respectively: 49 months for overall 
survival(Standard-Error (SE)=8) and 32 months for relapse 
free survival(SE=10). Two-year local-regional relapse and 
metastatic relapse free survivals were respectively 
59%(SE=10) and 74%(SE=10). Median body mass index (BMI) 
was 24.6(17.3–38) before treatment and 23, 24 after 
treatment(16.3–34.7). Median weight variation was 4 
kilograms(-16 to +6). Ninety-four percent of patients had 
nutritional support: 37.8% had oral nutritional supplements 
only, 56.8% had enteral nutrition and 2.7% parenteral 
nutrition. Skin reaction and mucositis were the major 
toxicities recorded. Toxicities details are reported in table 1 
 
 
Conclusion: Concomitant radiotherapy and cetuximab seems 
to be an effective therapy in the elderly population with 
encouraging results similar to the literature concerning its 
efficacy and toxicity. This treatment should be considered 
for patients > 70 years. 
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Purpose or Objective: In an era of personalized treatment 
there is a great interest in identifying factors which might 
help to predict patient response to RT. EGFR role in this 
